To be sold by retail on prescription of a specialist only.

Cisatracurium Besylate Injection USP

CISBLOK
COMPOSITION:
CISBLOK 10 (10 mg / 5 ml)
Each ml contains:
Cisatracurium Besylate USP
Equivalent to Cisatracurium 2 mg
Water for Injections I.P.

CISBLOK 20 (20 mg / 10 ml)

Each ml contains:
Cisatracurium Besylate USP
Equivalent to Cisatracurium 2 mg
Benzyl Alcohol I.P. 0.90 %v/v
(as preservative)
Water for Injections I.P. q.s.

DOSAGE FORM: Injection

DESCRIPTION
CISBLOK (Cisatracurium Besylate) is a nondepolarizing type of skeletal muscle relaxant meant for
intravenous administration. It has an intermediate onset and duration of action as compared to
neuromuscular blocking agents. Cisatracurium besylate is one of 10 isomers of atracurium besylate and
constitutes approximately 15% of that mixture.

INDICATION:
Indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal
muscle relaxation during surgery.

DOSAGE AND METHOD OF ADMINISTRATION:

CISATRACURIUM SHOULD ONLY BE ADMINISTERED INTRAVENOUSLY. IT IS NOT MEANT TO BE USED IN
NEONATES.
The dosage information provided below is meant only as a guide. Doses of cisatracurium should be
individualized in every patient. A peripheral nerve stimulator when used for such individualization will
permit the most advantageous use of cisatracurium, minimize the possibility of underdosing or
overdosing, and will aid in the evaluation of recovery.

ADULTS
Initial Doses
One of two intubating doses may be chosen: 0.15 (3 x ED95) and 0.20 (4 x ED95) mg/kg. (ED95 is the
dose required to produce 95% suppression of the adductor pollicis muscle twitch response to ulnar
nerve stimulation). Both these doses have been reported to produce GOOD or EXCELLENT conditions for
intubation when used as components of a propofol/nitrous oxide/oxygen induction-intubation